Safe for Use in Memory Clinics

Leqembi Found Safe for Use in Memory Clinics: A Step Forward in Alzheimer’s Treatment Accessibility. Leqembi (lecanemab), a monoclonal antibody developed by Eisai and Biogen, has recently been recognized as safe for use in memory clinics, marking a significant advancement in the treatment of early-stage Alzheimer's disease

Leqembi (lecanemab), a monoclonal antibody developed by Eisai and Biogen, has recently been recognized as safe for use in memory clinics, marking a significant advancement in the treatment of early-stage Alzheimer’s disease. This development enhances the accessibility of disease-modifying therapies for patients experiencing mild cognitive impairment or mild dementia due to Alzheimer’

Clinical Efficacy and Safety Profile

Leqembi targets and clears amyloid-beta protofibrils, toxic proteins implicated in Alzheimer’s progression. The Clarity AD Phase 3 trial demonstrated that Leqembi reduced cognitive decline by 27% over 18 months, as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB). Additionally, patients showed a 37% lesser decline in daily functioning compared to placebo, according to the Alzheimer’s Disease Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS MCI-ADL) .

Safety concerns, particularly amyloid-related imaging abnormalities (ARIA), such as brain swelling (ARIA-E) and microhemorrhages (ARIA-H), were noted. However, these events were generally mild to moderate and occurred predominantly within the first six months of treatment. Patients with one or no copies of the ApoE4 gene exhibited lower rates of ARIA, leading to recommendations for genetic screening prior to therapy initiation .

Regulatory Approvals and Implementation

Leqembi received accelerated approval from the U.S. Food and Drug Administration (FDA) in January 2023, with full approval granted in July 2023. Subsequently, it has been authorized in several countries, including Japan, China, South Korea, and the European Union. The European Medicines Agency (EMA) approved Leqembi for patients with early Alzheimer’s disease who have one or no copies of the ApoE4 gene, reflecting a favorable risk-benefit assessment in this population .

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) authorized Leqembi for private prescription. However, the National Institute for Health and Care Excellence (NICE) declined to include it in the National Health Service (NHS) due to concerns over cost-effectiveness .

Administration and Future Developments

Leqembi is administered via intravenous infusion, initially every two weeks for 18 months. To enhance patient convenience, the FDA approved a maintenance dosing regimen in January 2025, allowing for monthly infusions after the initial period . Additionally, a subcutaneous autoinjector is under review, which would enable weekly self-administration, potentially improving adherence and accessibility.

Integration into Memory Clinics

The incorporation of Leqembi into memory clinic practices necessitates a multidisciplinary approach, including neurologists, radiologists, and genetic counselors. Patients require thorough evaluation to confirm early-stage Alzheimer’s disease and determine ApoE4 status. Regular MRI scans are essential to monitor for ARIA during treatment.

Despite logistical challenges, the integration of Leqembi into clinical settings represents a significant advancement in Alzheimer’s disease management. Its ability to slow cognitive decline offers patients and families a meaningful opportunity to preserve function and quality of life during the early stages of the disease.

As research continues and real-world data accumulate, Leqembi’s role in Alzheimer’s therapy is expected to evolve, potentially in combination with other treatments targeting different aspects of the disease pathology.

Conclusion

The recent findings confirming Leqembi’s safety and effectiveness in memory clinic settings mark a major milestone in the treatment of Alzheimer’s disease. As one of the first disease-modifying therapies to demonstrate a clear ability to slow cognitive decline in early-stage patients, Leqembi offers new hope to millions affected by this debilitating condition. With proper monitoring, genetic screening, and support from multidisciplinary teams, its implementation in real-world clinical settings is both feasible and beneficial. While challenges remain in terms of cost and accessibility, especially in public healthcare systems, the growing global approvals and ongoing research signal a positive shift toward more accessible and impactful Alzheimer’s care. Leqembi represents not just a scientific breakthrough, but a step forward in preserving dignity, independence, and quality of life for patients and their families.